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a b s t r a c t 
Background: Advanced cystic fibrosis lung disease (ACFLD) is common, is associated with reduced quality 
of life, and remains the most frequent cause of death in individuals with cystic fibrosis (CF). These con- 
sensus guidelines provide recommendations to the CF community on management of both common and 
unique issues that arise when individuals reach a state of ACFLD. 
Methods: The CF Foundation assembled a multidisciplinary expert panel consisting of three workgroups: 
Pulmonary management; Management of comorbid conditions; Symptom management and psychosocial 
issues. Topics were excluded if the management considerations did not differ in ACFLD from in the overall 
CF population or if already addressed in other published guidelines. Recommendations were based on a 
systematic literature review combined with expert opinion when appropriate. 
Results: The committee formulated twenty-three recommendation statements specific to ACFLD that ad- 
dress the definition of ACFLD, pulmonary and intensive care unit management, management of selected 
comorbidities, symptom control, and psychosocial issues. 
Abbreviation: ABPA, allergic bronchopulmonary aspergillosis; ACFLD, advanced cystic fibrosis lung disease; ACP, advance care planning; CF, cystic fibrosis; CKD, chronic 
kidney disease; ECLS, extracorporeal life support; ECFS, European Cystic Fibrosis Society; FEV 1 , forced expiratory volume in one second; GER, gastroesophageal reflux; ICU, 
intensive care unit; ISHLT, International Society for Heart and Lung Transplantation; NIV, noninvasive ventilation; P a CO 2 , arterial partial pressure of carbon dioxide; P v CO 2 , 
venous partial pressure of carbon dioxide. 
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Conclusions: These recommendations are intended to be paired with previously published management 
guidelines for the overall CF population, with the objective of reducing practice variability and improving 
overall care, quality of life, and survival in those with ACFLD. 
© 2020 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. 
This is an open access article under the CC BY-NC-ND license. 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
1. Introduction 
While the quality of life and survival of individuals with cys- 
tic fibrosis (CF) are improving, advanced CF lung disease (ACFLD) 
remains common and the most frequent cause of death. CF Foun- 
dation Patient Registry data show that the forced expiratory vol- 
ume in one second (FEV 1 ) is less than 40 percent predicted in 18% 
of patients who are age 30 years, and nearly 25% of those age 45 
years. ACFLD is associated with reduced quality of life, worsening 
clinical symptoms, increased exacerbations, and increased health- 
care utilization [ 1 , 2 ]. 
ACFLD-specific outcomes are improving for individuals with a 
FEV 1 < 30% predicted, but there remains an approximately 10% per 
year risk of death in this subset [3] . While lung transplantation 
may represent a key life-extending treatment, some with ACFLD 
may choose to forgo the option. In addition, many potential can- 
didates are not referred [ 4 , 5 ], and among those referred approx- 
imately 27% die without transplant due to barriers to candidacy, 
waiting list mortality, or other issues [3] . 
Despite its prevalence and importance, there is limited liter- 
ature directed specifically at the unique medical and psychoso- 
cial challenges facing individuals with ACFLD. Furthermore, clini- 
cal experience suggests variability in practice patterns pertaining 
to ACFLD management, with some aspects of recommended care 
shown to be inconsistently applied [4-6] . The goal of these Consen- 
sus Guidelines is to provide guidance for management of ACFLD. 
Recognizing that care must be customized to each individual, these 
recommendations aim to reduce practice variability, improve the 
quality of life and survival of those with ACFLD, and identify gaps 
in clinical knowledge where future research is needed. 
2. Methods 
The Cystic Fibrosis Foundation assembled a multidisciplinary 
team including pediatric, adult, and transplant pulmonologists, a 
gastroenterologist, palliative care specialist, pharmacist, respiratory 
therapist, nurse coordinator, social worker, dietitian, methodolo- 
gist, one parent, and two individuals with CF. The panel included 
20 members from the United States, one from Canada, and one 
from Switzerland. The committee met in October 2017 to outline 
the scope of the guidelines and divide into three working groups: 
(1) Pulmonary management; (2) Management of comorbid con- 
ditions; (3) Symptom management and psychosocial issues. PICO 
( P opulation, I ntervention, C ontrol, O utcome) questions were devel- 
oped to address important aspects of care unique to individuals 
with ACFLD. Importantly, the committee recognized that many as- 
pects of ACFLD management overlap with care that takes place 
during the process of referral for lung transplantation. For example, 
early discussions regarding transplant and screening for markers of 
disease severity such as hypoxemia were recently recommended 
in transplant referral guidelines [7] , but addressing these issues 
also represent critical aspects of ACFLD care itself. Therefore, the 
committee developed these guidelines to be used in parallel and 
consistent with the transplant referral guidelines of Ramos et al. 
[7] . Topics were otherwise not included if the management con- 
siderations did not differ in ACFLD from in the overall CF pop- 
ulation or if the topics were addressed in previously published 
guidelines. 
Workgroups conducted literature searches in PubMed for each 
PICO question between January-August 2018 (Supplement) and re- 
viewed the literature to inform their draft recommendation state- 
ments. For some topics, searches failed to identify high quality 
clinical studies, and in these cases recommendations were based 
largely on workgroup consensus. The committee reconvened in 
December 2018 to vote on statements. Although a formal Delphi 
method did not take place, each statement was presented and dis- 
cussed among the entire committee during which language could 
be modified prior to formal voting. Voting on all recommendation 
statements met the (a priori) voting threshold of 80% agreement. 
In May 2019 the guidelines were distributed to the European Cys- 
tic Fibrosis Society (ECFS), the International Society for Heart and 
Lung Transplantation (ISHLT), the CF Foundation’s medical listserv, 
and the CF Foundation’s Community Voice for a two-week public 
comment period, after which the committee responded to all feed- 
back and revised the manuscript as appropriate. To provide addi- 
tional perspective from outside of the U.S., an “International Con- 
siderations” section was composed using input from the interna- 
tional committee members (Switzerland, Canada), as well as the 
Healthcare Advisory Council of CF Canada, who also approved the 
final version of the guidelines in its entirety. 
3. Definition of advanced CF lung disease 
The committee sought to create a pragmatic definition of ACFLD 
encompassing non-transplanted individuals whose disease has pro- 
gressed to a level where alterations in care or increased attention 
to certain aspects of standard care are warranted ( Fig. 1 ). 
A systematic literature search identified CF articles that: (1) ex- 
plicitly defined “advanced” or “severe” lung disease; (2) addressed 
unique aspects of care that were felt by the respective authors to 
apply to more severe disease; or (3) identified characteristics as- 
sociated with worse outcome. An FEV 1 < 40% predicted was the 
most common defining criterion [8-10] , including its use to define 
“severe” disease in many CF Registries globally [ 1 , 2 , 11 , 12 ]. Based 
on this and other considerations found in the literature search, 
ACFLD is defined as: FEV 1 < 40% predicted when “stable” (not 
during a pulmonary exacerbation), OR referred for lung transplan- 
tation evaluation, OR one or more of the following characteris- 
tics: previous intensive care unit (ICU) admission for respiratory 
failure, hypercarbia, daytime oxygen requirement at rest (exclud- 
ing nocturnal use only), pulmonary hypertension, severe functional 
impairment from respiratory disease (New York Heart Association 
Class IV), six-minute walk test distance < 400 m ( Table 1 ). This 
definition yielded 100% voting consensus among members of the 
committee. The committee also recognizes that individuals who 
lose significant lung function as children likely have more aggres- 
sive disease than adults with similar decrements [ 7 , 13 ]. Although 
the committee concluded that its definition of ACFLD should ap- 
ply to all ages, some providers may choose to apply some of the 
recommendations earlier in children. 
Importantly, there may also be individuals with FEV 1 approach- 
ing 40% predicted who do not meet the above criteria but manifest 
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Fig. 1. Alterations in care when an individual progresses to ACFLD. CF = cystic fibrosis; ACFLD = advanced cystic fibrosis lung disease. 
Table 1 
Definition of advanced cystic fibrosis lung disease. 
1) Forced expiratory volume in one second < 40% predicted when stable 
OR 
2) Referred for lung transplantation evaluation 
OR 
3) One or more of the following characteristics: 
A) Previous intensive care unit admission for respiratory failure 
B) Hypercarbia (P a CO 2 > 50 mmHg on arterial blood gas OR P v CO 2 > 56 mmHg on venous blood gas) 
C) Daytime oxygen requirement at rest (excluding nocturnal use only) 
D) Pulmonary hypertension (pulmonary artery systolic pressure > 50 mmHg on echocardiogram or evidence of right ventricular 
dysfunction in the absence of a tricuspid regurgitant jet) 
E) Severe functional impairment from respiratory disease (New York Heart Association Class IV) 
F) Six-minute walk test distance < 400 m 
Table 2 
Additional clinical manifestations associated with worse prognosis and/or disease progression in cystic fibrosis. 
Frequent pulmonary exacerbations 
Rapid rate of decline of forced expiratory volume in one second 
Supplemental oxygen requirement with exercise or sleep 
Worsening malnutrition despite supplementation 
Infection with difficult to manage organisms 
Cystic fibrosis-related diabetes 
Pneumothorax 
Massive hemoptysis ( > 240 mL) requiring intensive care unit admission or bronchial artery embolization 
other characteristics associated with more rapid progression to se- 
vere disease ( Table 2 ). These individuals may also benefit from se- 
lective application of the guidelines. Table 3 
4. Discussion of consensus statements 
1. When individuals with CF meet criteria for ACFLD, the CF Foun- 
dation recommends routine advance care planning (ACP) con- 
versations with them and their caregiver(s), including com- 
munication about prognosis and goals of care, documentation 
of advance directives, and decision-making surrounding lung 
transplantation. 
Palliative care concerns are often underestimated in lung dis- 
ease. Although individuals with CF and caregivers report willing- 
ness and desire for earlier discussions, most ACP conversations oc- 
cur during acute illness and frequently near the end of life [6] . 
Some unique barriers to ACP exist in CF and especially ACFLD in- 
cluding variable disease progression among those with advanced 
disease, the potential for rapid deterioration in some individuals, 
and the perceived conflict between advanced planning and pur- 
suit of lung transplantation. Early introduction of palliative care 
in pulmonary disease is associated with more consistent ACP con- 
versations, reduced healthcare utilization, and improved symptoms 
without reducing survival [14-16] . Literature supports early ACP 
for individuals with CF even before or while pursuing transplant 
[16-19] , emphasizing that ACP conversations and aggressive treat- 
ments should not be mutually exclusive ( Fig. 1 ). Discussions should 
review goals of care, preferences for palliative interventions, and 
decision-making pertaining to potential ICU admission, mechani- 
cal ventilation, tracheostomy, and lung transplantation. Early dis- 
cussions also stand in accord with ECFS best practice recommen- 
dations [20] , where preemptively outlining goals of care is recom- 
mended and allows individuals to carefully consider their wishes 
pertaining to future treatment options (including those discussed 
in Recommendation Statements 6, 7, 9, 10). Advance directives may 
include a durable power of attorney/health care proxy or living 
will. Care planning conversations should ideally involve the pa- 
tient’s chosen caregiver(s). 
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Table 3 
Recommendation statements. 
Number Recommendation 
1 When individuals with CF meet criteria for advanced CF lung disease, the CF Foundation recommends routine advance care planning 
conversations with them and their caregiver(s), including communication about prognosis and goals of care, documentation of advance 
directives, and decision-making surrounding lung transplantation. 
2 The CF Foundation recommends that individuals with ACFLD undergo screening for hypoxemia on exertion and sleep, hypercarbia, and 
pulmonary hypertension. 
3 The CF Foundation recommends supplemental oxygen for individuals with advanced CF lung disease and exercise induced or nocturnal 
hypoxemia. 
4 The CF Foundation recommends consideration of nocturnal noninvasive ventilation for individuals with advanced CF lung disease and 
chronic hypercarbia. 
5 The CF Foundation found insufficient evidence to make a recommendation regarding the use of pulmonary vasodilator therapy in 
individuals with advanced CF lung disease and pulmonary hypertension. 
6 The CF Foundation recommends lung transplantation as a treatment option for individuals with advanced CF lung disease if congruent 
with goals of care. 
7 The CF Foundation recommends that individuals with advanced CF lung disease and acute respiratory failure be considered eligible for 
intensive care unit management regardless of transplant status if congruent with goals of care. 
8 The CF Foundation recommends that individuals with advanced CF lung disease and acute respiratory failure be considered for a trial of 
high flow nasal cannula oxygen and/or noninvasive ventilation. 
9 For individuals with advanced CF lung disease and acute respiratory failure requiring invasive mechanical ventilation, the CF Foundation 
recommends consideration of early tracheostomy when anticipated need for mechanical ventilation is more than 5–7 days and support 
remains congruent with goals of care. 
10 The CF Foundation recommends that individuals with advanced CF lung disease who develop refractory respiratory failure requiring 
invasive mechanical ventilation be considered for early transition to extracorporeal life support if congruent with goals of care. 
11 For individuals with advanced CF lung disease, the CF Foundation recommends a trial of continuous alternating inhaled antibiotics as 
dictated by bacterial pathogens identified in respiratory culture. 
12 The CF Foundation recommends that individuals with progressive advanced CF lung disease undergo screening for fungal pathogens in 
addition to standard microbiological screening. 
13 The CF Foundation recommends that individuals with advanced CF lung disease participate in a pulmonary rehabilitation program. 
14 The CF Foundation found insufficient evidence to make a recommendation regarding the use of systemic corticosteroids in individuals 
with advanced CF lung disease. 
15 The CF Foundation found insufficient evidence to make a recommendation regarding routine screening for gastroesophageal reflux in 
individuals with advanced CF lung disease. 
16 The CF Foundation recommends the use of enteral tube feeds for individuals with advanced CF lung disease and malnutrition after 
consideration of procedural risks versus benefits. 
17 For individuals with advanced CF lung disease with frequent prior and continuing exposure to nephrotoxic and ototoxic agents, the CF 
Foundation recommends increased monitoring for accumulating toxicity. 
18 The CF Foundation recommends that women with advanced CF lung disease contemplating pregnancy carefully consider the risks in 
consultation with high-risk obstetrics and CF providers. 
19 For individuals with advanced CF lung disease with indications for opioids, the CF Foundation recommends treatment in accordance with 
established Center for Disease Control guidelines; this should include monitoring for adverse effects, and consultation with pain and/or 
palliative care specialists as appropriate. 
20 For individuals with advanced CF lung disease and anxiety, the CF Foundation recommends management in accordance with the 
International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus 
statements for screening and treating depression and anxiety, reserving benzodiazepines for refractory symptoms or end of life symptom 
palliation. 
21 When individuals with CF meet criteria for advanced CF lung disease, and with subsequent changes in clinical or social status, the CF 
Foundation recommends a formal care conference involving caregiver(s) and selected team members to develop a plan for ongoing 
psychosocial support. 
22 In individuals with advanced CF lung disease, the CF Foundation recommends assessing the adequacy of financial resources at least 
biannually, and with changes in clinical or social status. 
23 For pediatric patients with advanced CF lung disease nearing the age of transition to an adult CF care program, the CF Foundation 
recommends formally outlining a transition plan that provides flexibility in timing and coordination of transfer. 
2. The CF Foundation recommends that individuals with ACFLD 
undergo screening for hypoxemia on exertion and sleep, hyper- 
carbia, and pulmonary hypertension (also see related Recom- 
mendation Statements 3–5). 
3. The CF Foundation recommends supplemental oxygen for indi- 
viduals with ACFLD with exercise induced or nocturnal hypox- 
emia. 
Screening for markers of severity in ACFLD can identify indi- 
viduals at higher risk for poor outcomes, help determine the tim- 
ing of lung transplant referral, and may direct specific therapies. 
Among these markers, nocturnal and exertional hypoxemia are as- 
sociated with worse prognosis [ 3 , 21-23 ]. Screening for hypoxemia 
in advanced lung disease is advised in recently published CF lung 
transplant referral guidelines as well as ECFS best practice recom- 
mendations [ 7 , 20 ]. Nocturnal and/or exertional supplemental oxy- 
gen in CF improves oxygenation with potential for slight worsen- 
ing of hypercarbia [24] . Oxygen use in ACFLD also improves ex- 
ercise capacity [25-27] and reduces absenteeism from school or 
work [28] , although no studies demonstrate improvements in mor- 
tality or exacerbations. A Cochrane review corroborated these find- 
ings [29] , with the authors commenting that the risk of hypercar- 
bia is likely clinically inconsequential. Consistent with lung trans- 
plant referral guidelines [7] , annual screening for hypoxemia us- 
ing six-minute walk test and nocturnal oximetry is thus advised. 
In accordance with U.S. Center for Medicare and Medicaid Services 
and most third party payer requirements [30] , supplemental oxy- 
gen should be prescribed for those who desaturate to ≤ 88% with 
ambulation or to ≤ 88% for ≥ five minutes with sleep. 
4. The CF Foundation recommends consideration of nocturnal 
noninvasive ventilation (NIV) for individuals with ACFLD and 
chronic hypercarbia. 
Like hypoxemia, chronic hypercarbia is also associated with 
mortality in CF, can be detected on screening, and its presence in 
CF is cited as an indication for lung transplant referral [ 7 , 22 , 23 , 31 ]. 
Nocturnal NIV for chronic hypercarbia in CF was shown in one 
high-quality randomized crossover trial to improve partial pressure 
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of carbon dioxide, dyspnea, and exercise tolerance [32] . Other se- 
ries similarly demonstrate improvements in symptoms, lung func- 
tion, or utility in bridging to lung transplant [33-36] . A Cochrane 
review corroborated these findings, also suggesting NIV as a use- 
ful adjunct to airway clearance [37] . Based on these observations 
and consistent with lung transplant referral guidelines [7] , it is rec- 
ommended that individuals with ACFLD undergo annual screening 
for hypercarbia using a venous blood gas. In accordance with U.S. 
Center for Medicare and Medicaid Services and most third party 
payer requirements [38] , if P v CO 2 is > 56 mmHg on venous blood 
gas a confirmatory arterial blood gas should be obtained. Nocturnal 
NIV should be considered in individuals with symptoms consistent 
with hypercarbia (including dyspnea, fatigue, morning headaches) 
AND: 
• P a CO 2 ≥ 55 mmHg 
OR 
• P a CO 2 50–54 mmHg AND nocturnal desaturation 
OR 
• P a CO 2 50–54 mmHg AND ≥ two hospitalizations in the pre- 
ceding year for hypercarbic respiratory failure. 
Additional studies are necessary to define the optimal carbon 
dioxide thresholds and specific modalities for NIV in individuals 
with ACFLD and hypercarbia. 
5. The CF Foundation found insufficient evidence to make a rec- 
ommendation regarding the use of pulmonary vasodilator ther- 
apy in individuals with ACFLD and pulmonary hypertension. 
Although the exact incidence is unknown due to varying defi- 
nitions, pulmonary hypertension is also associated with increased 
mortality in ACFLD [39-41] . Its detection by screening echocardio- 
graphy in CF is an indication for lung transplant referral [ 7 , 42 ]. 
Also consistent with transplant referral guidelines [7] , a baseline 
screening echocardiogram is therefore recommended for individu- 
als who develop ACFLD. Repeat echocardiogram should be consid- 
ered if clinical status worsens. Despite its importance, there is lim- 
ited literature on treatment of pulmonary hypertension in ACFLD. 
Sildenafil appears to be safe in CF and improves vascular endothe- 
lial function without impairing ventilation [ 43 , 44 ], but no data ex- 
ist on its clinical efficacy. Further studies are needed to evaluate 
the physiologic and clinical effects of pulmonary vasodilators in 
ACFLD. 
6. The CF Foundation recommends lung transplantation as a treat- 
ment option for individuals with ACFLD if congruent with goals 
of care. 
Although outcomes have improved [3] , ACFLD is associated with 
significant morbidity and reduced quality of life, and remains the 
most common cause of death in CF [ 1 , 2 ]. Lung transplant out- 
comes have also improved and multiple cohort studies demon- 
strate improved quality of life and survival with transplant for in- 
dividuals with ACFLD [45-47] . In fact, ISHLT data show that adults 
with CF have a median survival after lung transplant of 9.9 years, 
with nearly 30% surviving twenty years after transplant and post- 
transplant survival in CF exceeding that of the other commonly 
transplanted diagnoses [48] . The benefits of lung transplant are 
likely most pronounced in those who are severely impaired and 
have additional predictors of mortality. Thus, while not all individ- 
uals with ACFLD will be eligible, lung transplant should be consid- 
ered as a treatment option in ACFLD in conjunction with published 
referral guidelines [ 7 , 20 , 42 ]. 
7. The CF Foundation recommends that individuals with ACFLD 
and acute respiratory failure be considered eligible for ICU 
management regardless of transplant status if congruent with 
goals of care. 
Survival in CF after an ICU admission has improved compared 
to previous decades. Survival to hospital discharge is reported as 
high as 55% when lung transplant is an option [49] , and 10–
55% when transplant is not an option [49-52] . Despite improve- 
ment from the 1970s, prognosis after admission to the ICU remains 
guarded in individuals requiring mechanical ventilation, especially 
those with non-reversible conditions [53] . Careful discussion be- 
tween patients, families and healthcare teams is needed when ICU 
care is considered, particularly when lung transplant is not an op- 
tion [54] . 
8. The CF Foundation recommends that individuals with ACFLD 
and acute respiratory failure be considered for a trial of high 
flow nasal cannula oxygen and/or NIV. 
There is little evidence to assess the value of high flow oxygen 
or NIV in acute respiratory failure in CF. However, endotracheal in- 
tubation for mechanical ventilation leads to immobility, loss of gag 
reflex, sedation, and many secondary complications, which can po- 
tentially be mitigated with less invasive support. High flow oxygen 
and NIV are feasible and well tolerated as shown in a small study 
in CF patients [55] . Their benefit is also supported by literature in 
other diagnoses, including high flow oxygen for hypoxemic respira- 
tory failure [56] , and NIV for hypercarbic exacerbations of chronic 
obstructive pulmonary disease [57] . These modalities should there- 
fore be considered in individuals with ACFLD and acute respiratory 
failure prior to endotracheal intubation for mechanical ventilation. 
9. For individuals with ACFLD and acute respiratory failure requir- 
ing invasive mechanical ventilation, the CF Foundation recom- 
mends consideration of early tracheostomy when anticipated 
need for mechanical ventilation is more than 5–7 days and sup- 
port remains congruent with goals of care. 
The role for early tracheostomy in respiratory failure remains 
unclear [58] . However, early tracheostomy for patients anticipated 
to have prolonged mechanical ventilation may decrease sedation 
needs while improving airway clearance and mobilization. Based 
on this and collective experience among CF clinicians, early tra- 
cheostomy should be considered for individuals with ACFLD who 
are anticipated to require ventilatory support beyond 5–7 days. 
Communication with the pertinent transplant team(s) is advised 
for those pursuing or considering lung transplantation. 
10. The CF Foundation recommends that individuals with ACFLD 
who develop refractory respiratory failure requiring invasive 
mechanical ventilation be considered for early transition to ex- 
tracorporeal life support (ECLS) if congruent with goals of care. 
Outcomes with ECLS have improved with modern-era technol- 
ogy including “awake” single-cannula techniques that allow for 
reduced sedation, increased mobility, and improved mucus clear- 
ance. Several case series that include a large percentage of patients 
with CF describe ECLS as a bridge to lung transplant, with post- 
transplant survival after ECLS now exceeding earlier reports uti- 
lizing mechanical ventilation for bridging [59-61] . Additionally, al- 
though data are limited, ECLS has the potential to provide a bridge 
to recovery in rare patients with CF and acute respiratory failure. 
In view of these reports and clinical experience, individuals with 
ACFLD and refractory respiratory failure should be considered for 
ECLS as a bridge to lung transplant or recovery. Preceding discus- 
sion with the pertinent transplant team(s) and review of goals of 
care are mandatory. 
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11. For individuals with ACFLD, the CF Foundation recommends a 
trial of continuous alternating inhaled antibiotics as dictated by 
bacterial pathogens identified in respiratory cultures. 
Intermittent (28-day on/off) inhaled antibiotics are standard of 
care for individuals with CF and chronic airways infection [62] . A 
continuous regimen (often alternating between two different an- 
tibiotics, as dictated by organisms identified in respiratory cul- 
tures) may provide additional benefit to those with more se- 
vere disease. One randomized double-blind placebo-controlled trial 
in patients with CF and Pseudomonas aeruginosa failed to enroll 
enough patients as many centers were already using continuous 
regimens in some patients. Despite being underpowered, rates of 
total exacerbations and hospitalizations trended lower with con- 
tinuous regimens [63] . Another retrospective study showed deteri- 
oration in lung function before initiation of continuous antibiotics 
that improved after their introduction. ACFLD patients in this study 
were more likely to have received a continuous alternating regi- 
men [64] . No adverse effects were demonstrated in either study. 
A continuous alternating inhaled regimen should therefore be con- 
sidered in ACFLD for its potential benefit. It should also be recog- 
nized that some centers consider prolonged, even continuous in- 
travenous antibiotics in select individuals with ACFLD approaching 
lung transplantation, but the risks and benefits of this approach 
require further study. 
12. The CF Foundation recommends that individuals with CF and 
progressive advanced lung disease undergo screening for fungal 
pathogens in addition to standard microbiological screening. 
CF Foundation guidelines recommend microbiologic surveil- 
lance for bacteria (quarterly) and mycobacteria (yearly), and 
for allergic bronchopulmonary aspergillosis (ABPA) with annual 
laboratory evaluations [ 65 , 66 ]. The role of fungal pathogens 
other than Aspergillus fumigatus in ABPA are currently not well- 
understood, but organisms including Trichosporon, Scedosporium , 
and Lomentspora are associated with severe CF exacerbations and 
potentially worse transplant outcomes [ 67 , 68 ]. ECFS guidelines 
note the potential pathogenicity of A. Fumigatus in some patients 
and advise that fungal cultures be available [20] , though no spe- 
cific recommendations are made for individuals with ACFLD. Based 
on these points, annual culture of sputum specifically for fungus is 
advised in individuals with progressive ACFLD and continued dete- 
rioration despite optimization of usual therapies. Further study is 
needed to better understand the implications of fungal pathogens 
in CF. 
13. The CF Foundation recommends that individuals with ACFLD 
participate in a pulmonary rehabilitation program. 
Multiple studies have evaluated exercise programs at home and 
in healthcare settings in individuals with CF including ACFLD. Both 
strength and aerobic training improve exercise capacity and qual- 
ity of life, and some studies demonstrate small improvements or 
slowing in the rate of decline in lung function [69-71] . Although 
data on pulmonary rehabilitation programs specifically in CF are 
limited, enrollment may also be beneficial in preparation for lung 
transplantation and is required by some transplant programs [72] . 
Pulmonary rehabilitation should therefore be considered for pa- 
tients with ACFLD. 
14. The CF Foundation found insufficient evidence to make a rec- 
ommendation regarding the use of systemic corticosteroids in 
individuals with ACFLD. 
Previous general CF guidelines recommend against routine, 
chronic oral corticosteroids for individuals with CF without asthma 
or ABPA [ 20 , 62 ]. One long-term randomized trial of high-dose ev- 
ery other day oral corticosteroids in mild-to-moderate CF lung dis- 
ease showed slightly better preservation of lung function compared 
to placebo, but growth retardation and abnormalities of glucose 
metabolism were seen in steroid-treated patients [73] . One short- 
term trial involving 20 adults with stable ACFLD showed no bene- 
fit from steroids, and deterioration in lung function was seen after 
steroids were withdrawn [74] . Cochrane reviews corroborate these 
results [75] , but no relevant, high quality data exists in ACFLD. One 
additional consideration in ACFLD, as discussed in ECFS guidelines 
[20] , is that due to concerns regarding wound healing many trans- 
plant programs require that pre-transplant chronic corticosteroid 
doses be limited to < 15–20 mg (prednisolone equivalent) per day. 
Although a trial of systemic corticosteroids is often considered in 
ACFLD on a case-by-case basis, given the lack of data a recommen- 
dation cannot be made for or against this practice in the ACFLD 
population. 
15. The CF Foundation found insufficient evidence to make a rec- 
ommendation regarding routine screening for gastroesophageal 
reflux in individuals with ACFLD. 
Gastroesophageal reflux (GER), even when “clinically silent” in 
patients lacking typical symptoms is implicated in the pathogen- 
esis of some lung diseases including idiopathic pulmonary fibro- 
sis and bronchiolitis obliterans syndrome after lung transplanta- 
tion. Existing literature reports a high prevalence of GER in ACFLD 
with features including proximal acid and bile reflux, pulmonary 
micro-aspiration, lower esophageal sphincter weakness, and pro- 
longed clearance of refluxate [76-78] . Some CF studies (including 
small numbers with ACFLD) associate GER detected by pH test- 
ing or endoscopy with worse pulmonary outcomes [78-80] . Many 
transplant programs routinely screen candidates for GER [ 42 , 81 ], 
but evidence to support screening for asymptomatic GER in ACFLD 
is lacking. Some pre- and post-transplant pulmonary outcomes im- 
prove with surgical treatment of GER in a mixed advanced lung 
disease population [82] . However, without further data, no specific 
approach can be recommended in individuals with ACFLD. 
16. The CF Foundation recommends the use of enteral tube feeds 
for individuals with ACFLD and malnutrition after consideration 
of procedural risks vs benefits. 
Malnutrition is common in individuals with ACFLD [2] , is asso- 
ciated with worse pre- and post-lung transplant outcomes [ 83 , 84 ], 
and may factor into eligibility for lung transplant. Enteral feed- 
ing leads to weight gain and potential for better maintenance of 
lung function in CF including individuals with severe disease [85- 
88] . Published CF Foundation guidelines recommend nasoenteral 
tube feeding in individuals with CF who require short-term ( < 
3 months) nutritional repletion [89] . ECFS general guidelines add 
that nutritional rehabilitation can take at least 3–6 months [20] , a 
fact that may be especially relevant in ACFLD when caloric require- 
ments increase and oral intake may become more difficult. For 
long-term supplementation, guidelines recommend percutaneous 
or surgical tube placement with the statement that low FEV 1 is not 
an absolute contraindication [89] , but careful consideration should 
be made regarding the capacity for procedural recovery. Particular 
attention to post-procedure analgesia is important to allow effec- 
tive airway clearance therapy while avoiding opioid-induced res- 
piratory suppression and bowel obstruction. In ACFLD, preference 
should be given for non-surgical placement options by either in- 
terventional radiology or upper endoscopy. Consultation with anes- 
thesiology is advisable, and tube placement should be avoided or 
delayed during acute illness. Transpyloric feeding (gastrojejunal or 
jejunal) should be considered in individuals with gastroparesis, se- 
vere GER, and/or poor tolerance of gastric feeds [89] . There are 
limited data to guide the use of short or long term total parenteral 
nutrition in ACFLD. In addition, sufficient pancreatic enzyme re- 
placement therapy and maintenance of nutritional status is chal- 
lenging during critical illness, but the systematic review did not 
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identify literature supporting a specific enzyme replacement regi- 
men in ACFLD. 
17. For individuals with advanced CF lung disease with frequent 
prior and continuing exposure to nephrotoxic and ototoxic 
agents, the CF Foundation recommends increased monitoring 
for accumulating toxicity. 
With disease progression, individuals with CF often acquire re- 
sistant organisms and receive more frequent courses of antibiotics 
with higher cumulative exposure. Both ototoxicity and nephrotox- 
icity related to aminoglycosides and other antibiotics are impor- 
tant in ACFLD, particularly when chronic kidney disease (CKD) may 
impact lung transplant candidacy and outcomes. CKD may occur 
without a serum creatinine above the normal range, particularly 
in the setting of reduced muscle mass. One large registry study 
demonstrated an annual prevalence of CKD of 2.3% in individu- 
als with CF; this rate doubled with every 10-year increase in age 
[90] . In another study of 80 adolescents and adults with CF, be- 
tween 31–42% had impaired renal function that was strongly cor- 
related with aminoglycoside exposure and potentiated by use of 
intravenous colistin [91] . Due to risks as well as clinical efficacy, 
tobramycin is the preferred aminoglycoside for exacerbations in in- 
dividuals with Pseudomonas . Although some studies do not confirm 
a relationship between antibiotic exposure and renal insufficiency 
[ 90 , 92 ], given the antibiotic requirements and transplant implica- 
tions careful monitoring is advisable in ACFLD, particularly during 
administration of intravenous ototoxic or nephrotoxic drugs. 
18. The CF Foundation recommends that women with ACFLD con- 
templating pregnancy first carefully consider the risks in con- 
sultation with high-risk obstetrics and CF providers. 
Compared to the general non-CF population, pregnancy in CF 
is associated with an increased risk of perinatal complications in- 
cluding maternal deterioration, preterm labor, low birth weight, 
Caesarian delivery, respiratory failure, and death, with most stud- 
ies showing higher risks in those with ACFLD [93-95] . The asso- 
ciated maternal complications may be a function of the lung dis- 
ease itself, as outcomes in pregnant women with CF do not ap- 
pear to differ from outcomes in non-pregnant women with CF 
who have similar lung disease characteristics [96-99] . International 
guidelines regarding pregnancy in CF note that pregnancy can oc- 
cur regardless of severity of pulmonary disease, with outcomes (for 
mother and infant) being closely linked to lung function and stabil- 
ity. Pulmonary status needs to be optimized in planned fashion in 
all women prior to pregnancy [100] . Although predicting individual 
pregnancy outcomes based on disease severity is challenging [94] , 
it is advisable for women with ACFLD contemplating pregnancy to 
carefully discuss the risks prior to conception. 
19. For individuals with ACFLD with indications for opioids, the CF 
Foundation recommends treatment in accordance with estab- 
lished Center for Disease Control guidelines, including monitor- 
ing for adverse effects and consultation with pain and/or pal- 
liative care specialists as appropriate. 
Pain and dyspnea are common and associated with adverse out- 
comes in CF [101] . Concerns about respiratory depression, toler- 
ance, addiction, and transplant eligibility may affect opioid pre- 
scribing for patients with specific indications including moderate- 
severe acute or chronic pain, painful therapies, dyspnea in ACFLD, 
or end of life symptoms. In two CF studies (one in the ACFLD pop- 
ulation), no patients experienced severe opioid-induced respira- 
tory side effects, and subsequent misuse behaviors were extremely 
rare [ 102 , 103 ]. Studies in mixed pulmonary populations including 
COPD similarly demonstrated no significant respiratory side effects 
of low-dose opioids [ 104 , 105 ]. Another study of 59 lung transplant 
candidates co-managed in palliative care programs also found no 
important opioid side effects, and only 23% continued opioids one- 
month post-transplant [106] . Consistent with other statements for 
palliative care in lung disease [107] , appropriately-dosed opioids 
can be prescribed for individuals with ACFLD when coupled with 
proper education, safety monitoring, and proactive side effect man- 
agement including monitoring of bowel function and prevention 
of constipation. Communication with transplant centers regarding 
opioid policies is advised. Specific strategies regarding opioid ini- 
tiation, dosage, duration, and risks are reviewed in Center for Dis- 
ease Control Guidelines [108] . 
20. For individuals with ACFLD and anxiety, the CF Foundation rec- 
ommends management in accordance with the International 
Committee on Mental Health in Cystic Fibrosis: Cystic Fibro- 
sis Foundation and European Cystic Fibrosis Society consensus 
statements for screening and treating depression and anxiety, 
reserving benzodiazepines for refractory symptoms or end of 
life symptom palliation. 
Anxiety is common and warrants increased attention in ACFLD. 
Benzodiazepine use has been associated with exacerbations, res- 
piratory failure, and mortality in COPD [ 105 , 109 ], but CF-specific 
data are lacking. The International Committee on Mental Health in 
CF’s consensus statements recommend a stepped-care model, using 
psychological interventions as first-line anxiety treatment and re- 
serving short-term benzodiazepines for refractory symptoms with 
close monitoring [110] . Consistent with other palliative care state- 
ments for lung disease [107] , benzodiazepines should be consid- 
ered standard of care for anxiety at the end of life in individuals 
with ACLFD. 
21. When individuals with CF meet criteria for advanced lung dis- 
ease and with subsequent changes in clinical or social status, 
the CF Foundation recommends a formal care conference in- 
volving caregiver(s) and selected team members to develop a 
plan for ongoing psychosocial support. 
In adults with CF and severe disease, caregiver support is as- 
sociated with fewer physical and emotional symptoms [111] . Ad- 
ditionally, caregiver availability often factors into lung transplant 
eligibility based on pre-transplant support being linked to ad- 
herence and post-transplant outcomes in general organ trans- 
plant populations [ 42 , 112 ]. Moreover, family members of individu- 
als with CF face mental health challenges that may be amplified in 
ACFLD [ 113 , 114 ]. Proactive communication allows better prepared- 
ness while approaching complex health issues and decisions. Care 
teams should thus formally identify support systems for those with 
ACFLD, while normalizing the need for support and offering edu- 
cation on caregiver roles during disease progression and pursuit of 
transplantation. 
22. In individuals with ACFLD, the CF Foundation recommends as- 
sessing the adequacy of financial resources at least biannually 
and with changes in clinical or social status. 
Low socioeconomic status is associated with worse adherence, 
nutrition, lung function, mental health, and survival in CF [ 115 , 116 ]. 
Although the specific impact in ACFLD is unknown, experience 
suggests greater financial challenges including treatment burden 
and associated costs, change in work status, disability, and care- 
giver economic strain [117] . Public insurance, which typically cov- 
ers individuals with limited income, is also associated with lower 
lung transplant referral and acceptance rates [ 4 , 118 ], as well as in- 
creased wait list mortality [119] . The American College of Physi- 
cians, in a recent position paper, recommended increased screen- 
ing and collection of social determinants of health data for all pa- 
tients [120] . Therefore, more frequent assessment is indicated for 
individuals with ACFLD and their caregivers to identify cost barri- 
ers, provide resources, educate regarding health care coverage and 
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transplant fundraising if applicable, and reduce stigma associated 
with needing assistance. 
23. For pediatric patients with ACFLD nearing the age of transition 
to an adult CF care program, the CF Foundation recommends 
formally outlining a transition plan that provides flexibility in 
timing and coordination of transfer. 
Structured programs for transition to adult care are outlined in 
the CF literature and are associated with improved patient and 
family satisfaction, clinical stability during transfer, and reduced 
need for urgent transfer [ 121 , 122 ]. Programs for adolescents and 
young adults with ACFLD approaching transition should thus in- 
clude gradual preparation and proper coordination of transfer as 
described in the general CF population [123] . 
Overall concerns surrounding transition do not differ in ACFLD 
[124] , but many unique issues are pertinent including involvement 
of more specialists and multiple concurrent transitions, psychoso- 
cial and adherence concerns, and end of life considerations. Care- 
giver and psychosocial assessment should proceed as described in 
Recommendation Statements 21 and 22. Opinions vary on whether 
transition should be delayed in ACFLD [ 125 , 126 ], and there are 
no data to guide optimal timing. Adolescents and young adults 
nearing end of life may benefit from continuity with pediatric 
providers. In all others with ACFLD, proper coordination and flex- 
ibility are recommended with attention to patient factors and 
center-specific protocols [ 123 , 127 ]. 
5. International considerations 
ACFLD is also common and the most frequent cause of death in 
individuals with CF beyond the U.S. In Europe, by the FEV 1 thresh- 
old used in these guidelines, 2017 ECFS data indicate the presence 
of ACFLD in nearly 15% of adults with CF aged 18 to 29 years, and 
20% of those 30 years and older, with this latter prevalence exceed- 
ing 30% in several Eastern European countries [1] . ACFLD is simi- 
larly common in adults with CF in Australia and Canada, with these 
nations’ registries reporting a prevalence of 14% and 16%, respec- 
tively [ 11 , 12 ]. In children with CF across the world, the reported 
prevalence of ACFLD is much lower at approximately 1% in Aus- 
tralia and Canada, 2% in Europe as a whole, and 4% in 18-year-olds 
in the U.S [2] , but does vary by region even exceeding 10% in some 
Eastern European countries [1] . Moreover, although the prevalence 
and impact of ACFLD are difficult to estimate in less developed re- 
gions and/or those lacking robust registry data, many additional 
barriers to care may exist in these settings and contribute to more 
rapid disease progression [128] . Thus, ACFLD threatens the life and 
well-being of many people with CF globally, and improving care 
in this population should be an important priority for the interna- 
tional CF community. 
There is limited literature to guide whether management of 
ACFLD should be adapted to different regions of the world. Never- 
theless, several pertinent disparities should be appreciated in de- 
veloping and low-/middle-income countries including late diagno- 
sis, misdiagnosis, socioeconomic status, and access to medical ther- 
apies or lung transplantation [128] . For instance, the advent of 
highly effective CFTR modulator therapy represents a monumen- 
tal breakthrough for CF care, but accessing these expensive treat- 
ments globally will be extremely dependent on reimbursement 
policies and availability within individual healthcare systems. Even 
more specific to ACFLD, while the current guidelines endorse lung 
transplant consideration for those with advanced disease consis- 
tent with the European perspective [ 129 , 130 ], it is important to 
note that the availability of transplant varies significantly around 
the world for individuals with CF and other diagnoses. In fact, of 
47,591 total lung transplants recorded in the ISHLT Thoracic Trans- 
plant Registry between 2005 and 2018, approximately 56% took 
place in North America, 36% in Europe, but only 8% elsewhere [48] . 
Even within Europe, the percentage of individuals with CF who re- 
ceive lung transplant varies significantly, particularly when com- 
paring European Union to non-European Union countries [1] . These 
differences certainly have the potential to influence the develop- 
ment, progression, and available treatment options for ACFLD, and 
thus, the current guidelines need to be applied in the context of 
an individual patient and healthcare provider’s global setting. 
Even in developed countries where access to therapies is sim- 
ilar, it is necessary to interpret these guidelines within their in- 
ternational context, whereby comparisons with international trans- 
plant referral guidelines [ 7 , 42 ] and recently revised ECFS Best Prac- 
tice Guidelines [20] are useful. The recently published CF trans- 
plant referral guidelines emphasize a pre-emptive approach to 
screening for markers of disease severity, transplant consideration, 
and intervening on modifiable barriers to transplant [7] . The issue 
of late or non-referral exists globally even among developed coun- 
tries, with one study from France demonstrating that at least 40% 
of individuals with ACFLD who died were referred for transplant 
late or not at all [5] . The current guidelines were therefore de- 
signed to provide consistency with these previously published doc- 
uments, recommending identical screening for markers of disease 
severity, while also elaborating on management of hypoxemia and 
hypercarbia. Similarly, although the ECFS Guidelines [20] do not of- 
fer specific focus on ACFLD, general recommendations on several 
pertinent topics including nutritional rehabilitation, antibiotic ther- 
apy and complications, and oxygen screening and therapy are all 
consistent with the current manuscript. Notably, when managing 
acute respiratory failure, the European document advises caution 
against invasive mechanical ventilation in individuals without a 
clearly reversible precipitant, especially those who have not previ- 
ously completed transplant evaluation. Recommendations 7–10 in 
the current guidelines pertaining to ICU management should thus 
be interpreted in the framework of the available means of sup- 
port in a given care setting. Finally, our emphasis on preemptive 
and routine ACP in individuals with ACFLD are similar to the Eu- 
ropean perspective, although clinical experience suggests that end- 
of-life and palliative care concerns are not frequently enough em- 
phasised around the world, and thus represent an area of need for 
the global CF community. 
6. Conclusions 
Outcomes for individuals with CF are improving, and contin- 
ued research and therapeutic advances are predicted to bring fur- 
ther improvements in upcoming years. However, CF by nature re- 
mains a progressive disease; even with the landmark development 
of new CFTR modulator therapy, some individuals will not be eli- 
gible, long-term efficacy remains unknown and responses may be 
heterogeneous, and many with CF today already have established 
advanced lung disease. ACFLD will therefore continue to be an im- 
portant issue and carries many pulmonary, general medical, trans- 
plant surgical, psychosocial, economic, and palliative care concerns. 
These guidelines intend to provide direction to CF care teams on 
the unique management concepts, which should be considered and 
paired with standard care when individuals reach a state of ad- 
vanced disease ( Fig. 1 ). Moreover, as the CF community strives to 
improve outcomes, more research specific to the manifestations 
of ACFLD is needed, particularly as the CF population ages and 
extra-pulmonary considerations become more important. For now, 
providers should use these guidelines when partnering with their 
patients with ACFLD to determine the best treatment plan for each 
individual, with an ultimate goal to further improve quality of life 
and survival for individuals with CF. 
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